CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
Press releases
These press releases are intended for business journalists and analysts/investors
Bushfire crisis response from GSK Australia
We are all deeply saddened at the devastation caused by the Australian bushfires and the impact on people and wildlife in affected communities, particularly in the states of Queensland, New South Wales, Victoria and South Australia.
Read more - Bushfire crisis response from GSK Australia Read more
Australian researcher uncovering keys to malaria elimination receives major research award
Professor Brendan Crabb wins 2019 GSK Award for Research Excellence
“There is probably no more impactful contribution to human development than ridding the world of malaria,” says winner
GSK Australia launches Spectrum: resource group for LGBT+ employees and straight allies
The global GSK employee resource group for LGBTQI employees and their straight allies, known as Spectrum, was launched in Australia at an event at the company’s Pharmaceuticals headquarters in Melbourne today.
Important update for health care professionals re: expiry date of Priorix, our measles, mumps and rubella vaccine
GlaxoSmithKline Australia (GSK), in consultation with the Therapeutic Goods Administration, would like to provide the following information to ensure that there is no confusion in relation to the expiration date of measles, mumps and rubella vaccine (MMR), Priorix.
Andrew Jenkin to Lead new GSK Consumer Healthcare Joint Venture in ANZ
Andrew Jenkin has been appointed General Manager GSK Consumer Healthcare, ANZ. The appointment comes after GSK and Pfizer closed the transaction to create a new consumer healthcare Joint Venture yesterday.
Read more - Andrew Jenkin to Lead new GSK Consumer Healthcare Joint Venture in ANZ Read more
New once-daily treatment option reimbursed for patients with asthma
ARNUITY ELLIPTA (fluticasone furoate), once-daily maintenance therapy for asthma reimbursed by the PBS in Australia
Read more - New once-daily treatment option reimbursed for patients with asthma Read more
Policy debate needed to ensure Australia remains a global leader in public access to life saving vaccines
Australia’s National Immunisation Program (NIP) is one of the world’s best, achieving some of the highest vaccination rates in the world and supporting community protection against a wide range of vaccine preventable diseases. However, Australia’s timely access to life saving vaccines is under increasing challenge, as the system that assesses which vaccines are included on the NIP falls behind other countries on some issues and may not always match with how the community values prevention.
GSK statement on ACCC Federal Court judgment
Read more - GSK statement on ACCC Federal Court judgment Read more
GSK Australia reports 2018 results to ASIC
Read more - GSK Australia reports 2018 results to ASIC Read more
